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Abstract: The growth of human papillomavirus (HPV)-transformed cells depends on the ability of the
viral oncoproteins E6 and E7, especially those from high-risk HPV16/18, to manipulate the signaling
pathways involved in cell proliferation, cell death, and innate immunity. Emerging evidence indicates
that E6/E7 inhibition reactivates the host innate immune response, reversing what until then was an
unresponsive cellular state suitable for viral persistence and tumorigenesis. Given that the disruption
of distinct mechanisms of immune evasion is an attractive strategy for cancer therapy, the race is
on to gain a better understanding of E6/E7-induced immune escape and cancer progression. Here,
we review recent literature on the interplay between E6/E7 and the innate immune signaling pathways
cGAS/STING/TBK1, RIG-I/MAVS/TBK1, and Toll-like receptors (TLRs). The overall emerging
picture is that E6 and E7 have evolved broad-spectrum mechanisms allowing for the simultaneous
depletion of multiple rather than single innate immunity effectors. The cGAS/STING/TBK1 pathway
appears to be the most heavily impacted, whereas the RIG-I/MAVS/TBK1, still partially functional in
HPV-transformed cells, can be activated by the powerful RIG-I agonist M8, triggering the massive
production of type I and III interferons (IFNs), which potentiates chemotherapy-mediated cell killing.
Overall, the identification of novel therapeutic targets to restore the innate immune response in
HPV-transformed cells could transform the way HPV-associated cancers are treated.
Keywords: human papillomavirus; HPV; innate immunity; E6 and E7 oncoproteins; HPV-driven
cancer; pathogen recognition receptors; PRR
1. Introduction
Human papillomaviruses (HPVs) are small, non-enveloped double-stranded DNA viruses
responsible for the development of cancers of the anogenital and upper aerodigestive tract, with
an incidence of ~5% among all cancers worldwide. The HPV genome is a circular double-stranded
DNA episome containing one regulatory region and two early (E) and late (L) open reading frames
(ORFs). Among early proteins, E6 and E7, the only two viral genes consistently found in cervical
tumors, are required for the development of HPV-associated cancer. The transforming activity of
these two oncoproteins is mediated primarily through protein–protein interactions conducive to a
replication-competent environment that also includes the dampening of the innate immune response.
Although anogenital HPV infections affect ~80% of the population during their lifetime, they are
cleared for the most part by the host immune system through a process that can take up to 1–2 years
from the initial infection, with just a minority of infected individuals developing HPV-associated
tumors. The deregulated expression of the two viral oncoproteins E6/E7 is necessary for tumor
development and maintenance. A plethora of studies have extensively demonstrated the molecular
mechanisms through which E6/E7 facilitate the accumulation of genetic mutations and chromosome
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abnormalities leading to cancer development, as reviewed elsewhere [1–12]. Conversely, even though
escape from innate immune surveillance appears to be the hallmark of persistent HPV infection,
our knowledge on the interplay between E6/E7 oncoproteins and the mediators of innate immunity in
keratinocytes is still limited and has just started to be unraveled.
In light of the above, this review will provide an overview of recent studies bridging E6/E7-mediated
inhibition of innate antiviral immunity and cancer progression. Understanding how the deregulated
expression of E6/E7 can efficiently subvert innate and adaptive immunity may pave the way for the
development of novel anticancer strategies aimed at restoring cellular reactivity in HPV-transformed
cells. In this review, we summarize a growing body of literature highlighting the biological relevance
of E6/E7 as suppressors of the innate immune response in HPV-driven tumorigenesis.
2. HPV Infection and Human Carcinogenesis
HPVs are a heterogeneous group of non-enveloped DNA viruses responsible for various types of
skin and mucous membrane lesions, which generally heal without requiring any medical intervention
despite retaining the potential to evolve into invasive cancers under certain conditions. HPVs have
a circular double-stranded DNA genome of ~8 kb that includes non-structural E and structural L
genes. To date, over 200 different types of HPV have been identified and classified into several
phylogenetic groups [13]. Of these, mucosal HPVs belonging to the α-genus associated with infections
of mucosal epithelia are the best characterized. They can be grouped into ‘low-risk’ and ‘high-risk’ types,
depending on the relative propensity of the resulting neoplasms to undergo malignant progression,
as reviewed elsewhere [3,4,14–17].
Although a dozen HPV types belonging to the mucosa-infecting alpha genus have been classified
by the WHO as carcinogenic, the two most commonly found HPV types in cervical cancer are
HPV16 (~50%) and HPV18 (~15%), which alone accounts for over 500,000 new cancer cases and
over 250,000 cancer deaths per year worldwide. In addition, a significantly increasing prevalence
of HPV-driven oropharyngeal cancers (OPSCCs) has been observed over the past few decades in
western countries, with HPV16 being the most frequently found genotype. According to several
studies, the impact of HPV infection on oropharyngeal cancer development is projected to exceed that
of environmental factors in these regions [1,16–20].
In principle, HPV-driven cancer could be prevented by vaccination against oncogenic HPV types.
There are in fact three currently available prophylactic vaccines on the market that efficiently protect
against infection with the most common oncogenic HPV types. However, despite this encouraging
outlook, there are still important issues to be dealt with, such as vaccine hesitancy—only a small
minority (7.5%) of females worldwide, aged 10–20 years, are estimated to have received at least one
shot of an HPV vaccine [8,15,17]. In addition, given that HPV-driven carcinogenesis is the result of
persistent infection with oncogenic HPV types, often lasting several decades, it is highly likely that
HPV-associated tumors will remain a major health concern for the foreseeable future, thus requiring
novel effective therapeutic solutions [21–26]. In this context, feasible therapeutic options may include
the restoration of the innate immune response in HPV-transformed cells. Thus, more efforts should be
put in place to mechanistically dissect the cross talk between epithelial innate immunity and E6/E7
proteins in order to unveil potential therapeutic targets.
The transforming activity of E6 and E7 oncoproteins is mediated primarily through protein–protein
interactions conducive to a replication-competent environment eventually leading to cancer. A plethora
of interactome analyses of high-risk (hr) genotypes have identified hundreds of cellular proteins
potentially interacting with E6 and/or E7, probably reflecting the large number of biological functions
exerted by these two viral oncoproteins. Obviously, the most relevant biological activity of these
oncoproteins is inactivation of the tumor suppressors p53 and pRb. In particular, E6 mediates the
proteasomal degradation of p53, thereby disrupting its ability to induce cell cycle arrest and apoptosis
in stressed cells. Similarly, E7 targets pRb for degradation, promoting the transcriptional activation of
S-phase genes by E2F. For a more exhaustive review of this topic, see [3,6,7,15,27–33].
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3. Keratinocytes as Mediators of Innate Immunity Against HPV Infection
The innate immune response is the first line of defense against microbial pathogens. To detect
and respond to the invading pathogens, cells utilize specialized receptor proteins, defined as pattern
recognition receptors (PRRs), which bind to pathogen-associated molecular patterns (PAMPs),
a set of viral proteins and nucleic acids, including double-stranded RNA, single-stranded RNA,
CpG unmethylated DNA and 5′ triphosphorylated RNA (ppp-RNA) [34–44].
Based on their location, PRRs are classified as membrane-bound or unbound intracellular receptors.
The former comprises Toll-like receptors (TLRs) and C-type lectin receptors (CLRs), which are located at
the surface of cells or endocytic compartments. The latter includes leucine-rich repeat (LRR)-containing
(or NOD-like) receptors (NLRs), RIG-I-like receptors (RLRs) and the AIM2-like receptors (ALRs), which
are located in the cytoplasm to sense intracellular pathogens. Furthermore, a panel of structurally
unrelated cytosolic DNA sensors has been identified, among which the most relevant is the enzyme cyclic
guanosine monophosphate–adenosine monophosphate (cyclic GMP–AMP) synthase (cGAS), which in
bound conformation with double-stranded DNA (dsDNA) catalyzes adenosine 5′-triphosphate (ATP)
and guanosine 5′-triphosphate (GTP) into cyclic GMP–AMP (2′3′-cGAMP). This second messenger
binds to and activates the stimulator of interferon genes (STING), a scaffold protein localized on
the endoplasmic reticulum (ER) membrane. Although PRRs are different in terms of structure, the
point of sensing and adaptor partner, they considerably overlap in their use of downstream signaling
components and enzymatic pathways, ultimately leading to the activation of the transcription factors
NF-κB and IRF3/7. While NF-κB triggers transcriptional activation of pro-inflammatory cytokines and
chemoattractant cytokines and chemokines, IRF3/7 induces type I (IFNβ) and III (IFNλ) interferons
(IFNs). IFNs are then key autocrine and paracrine regulators of the antiviral state thanks to their
ability to induce a plethora of interferon-stimulated genes (ISGs) that can inhibit viral replication while
triggering cell growth arrest and apoptosis [34,35,45–65].
The natural target cells of HPV are keratinocytes that form the stratified squamous epithelium
of the skin and mucosal sites (e.g., the ano-genital or upper respiratory tract). Despite the fact that
keratinocytes express several PRRs, which are able to sense viral pathogens and promote the innate
immune response, HPVs have been very successful throughout evolution in creating an unreactive
cellular milieu suitable for viral replication, persistence, and tumorigenesis [66–82].
The consensus model of cervical cancer progression clearly indicates as unifying risk factors the
establishment of a persistent infection by hrHPV genotypes and the deregulation of normal viral gene
expression, leading to steady-state E6/E7 overexpression. It is now widely accepted that HPV viral
DNA integrates into the host genome quite frequently, especially during persistent HPV infection by hr
genotypes. This event in turn stabilizes transcription of E6 and E7, thus conferring a growth advantage
to the host cells. Despite the fact that approximately 90% of all HPV infections are resolved by the host
immune system within a 2-year period, some patients may develop persistent HPV infections for years
and eventually develop cancer, thus indicating that the innate immune reaction of the infected cells
has been impaired in these cases. Even though the molecular determinants of this deficient immune
response are potentially druggable targets to restore the innate immune response in HPV-transformed
cells, they are still poorly characterized [2,3,6,8,15–17,76,83,84].
A major obstacle to understanding the true impact of E6/E7 on the host immune response is
the difficulty in putting together pieces of data obtained using different experimental model and cell
lines, which can easily create bias, especially when dealing with innate immunity. Indeed, current
experimental models to study HPV-associated tumors are notoriously flawed by a number of limitations,
mostly because HPV can only replicate and complete its life cycle in stratified squamous epithelial
sites, which are quite difficult to model in vivo. Moreover, HPV can complete its viral life cycle in vitro
only when keratinocytes are grown in organotypic raft culture, but, even in this case, the efficiency of
viral replication is usually quite low. To further complicate matters, no animal model of infection is
currently available for hr human genotypes (e.g., HPV16 and HPV18). Thus, the study of the cross
talk between HPV and host cells has been mostly carried out in keratinocytes grown as monolayers.
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This cell system unfortunately has a series of caveats affecting the interpretation and generalizability of
the findings, with the heterogeneity of the model of HPV infection being at the top of the list. In short,
currently available cell models of HPV infection/transformation are based on the following strategies:
(i) infection with HPV16 pseudovirions or virions; (ii) lentiviral-mediated overexpression of E6 and E7
from HPV16 or HPV18 by; (iii) transfection with episomal viral genomes; and (iv) transformed cells
harboring multiple copies of the integrated or episomal viral genome.
With regard to HPV-associated disease models, it is particularly crucial to distinguish between
models of infection where the viral genome is replicating in the infected cells and those where the
pathogenic impact of the virus is solely due to deregulated E6/E7 expression. This latter model
appears to fully recapitulate the status of HPV-transformed cells given that the viral genome is no
longer replicating and, in most cases, is integrated as a partial genome. This condition can also be
artificially obtained when cells are stably transduced with retroviral vectors expressing E6 and E7
or in proliferating cells stably maintaining episomal viral genomes after several passages in culture.
The interface or interplay of the virus with the host innate immune system under these two different
physical statuses of the virus, also characterized by a distinct pattern of viral protein expression, has
not been fully elucidated yet. In addition, while a number of excellent reviews have already addressed
the events occurring during the early phases of HPV infection, describing the cross talk between
the host cell innate immune system and viral replication, there is lack of reviews focusing on the
molecular mechanisms underlying the E6/E7-mediated dampening of the innate immune response in
HPV-transformed keratinocytes, where these oncoproteins are aberrantly regulated [72–76,85]. Thus,
here we take a close look at recent advances showing how viral immune escape mechanisms may
contribute to the development and maintenance of a transformed phenotype during HPV-driven
carcinogenesis. Since HPV16 and HPV18 account for almost 70% of all HPV-associated cancers, our
analysis will be predominantly focused on the literature dealing with these two genotypes [1,16–18,86].
4. Impact of E6/E7 on the Innate Immune Response
A series of reports dating back to the first decade of the 2000s showed that hrHPVs inhibit several
ISG transcripts, mainly through E6/E7. The fact that many of these targeted ISGs were involved in the
antiviral response led us to hypothesize that the virus could establish a persistent state of infection
conducive to cancer development by evading host immunosurveillance [71,87–89].
Important insights into the molecular mechanisms of viral immune evasion came from studies
showing how E6/E7 proteins could bind and inactivate transcription factors, such as IRF1, IRF3, and
STAT1, thereby influencing either the transcriptional activation of IFN genes or the downstream IFN
receptor pathways that lead to the transcriptional activation of ISG genes [70,71,73,76,79,88,90–93].
These findings, together with a better understanding of the underlying mechanisms of the PRR-mediated
induction of IFN, further supported the hypothesis that E6/E7 oncoproteins played a central role
in manipulating the cellular environment to create an unreactive state suitable for uncontrolled
cell proliferation.
The sections below summarize emerging evidence of the impact of E6/E7 viral proteins on the
three major innate immune signaling pathways, namely cGAS/STING/TANK binding kinase-1 (TBK1),
RIG-I/MAVS/TBK1, and TLRs, regulating the transcriptional activation of IFNs, pro-inflammatory
cytokines, and chemokines in response to exogenous stimuli. We will mainly focus on nucleic acid
recognition mechanisms and downstream signaling, highlighting the strategies devised by hrHPVs to
escape from innate immunity and drive carcinogenesis. For quick reference, these data have also been
listed in Table 1.
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Table 1. Impact of E6/E7 oncoproteins from HPV16/18 on innate immunity signaling pathways.
Mechanism or Target Cellular Model Reference
cGAS/STING/TBK1 signaling pathway
HPV18 E7 binds and antagonizes STING. HeLa cells and mouse embryo fibroblasts stably transduced withHPV18 E6 or E7 expressing retroviruses. Lau, L. et al., 2015 [94]
Epigenetic silencing of cGAS and STING genes through
HPV16/18 E7-mediated induction of the methyltransferase
SUV39H1.
HeLa, CaSki, NIKSmcHPV18 and HEK 293 cells expressing either
HPV16 or HPV18 E6 and E7. Albertini, S. et al., 2018 [95]; Lo Cigno, I. et al., 2020 [96]
HPV16 E7 hijacks NLRX1 to induce STING degradation via
an autophagy-dependent mechanism.
HNSCC-derived cell lines ectopically expressing HPV16 E7 and a
syngeneic C57/BL/6 model of HPV+ HNSCC. Luo, X. et al., 2019 [97]
The H3K4 lysine demethylases KDM5B and KDM5C
epigenetically suppress STING mRNA expression levels. Breast cancer cells, HPV
+ head and neck and cervical carcinomas. Wu, L. et al., 2018 [98]
Impaired IFNβ gene transcriptional activation upon
stimulation with STING agonists. HPV16
+ HNSCC-derived cell lines. Shaikh, M.H. et al., 2019 [99]
RIG-I/MAVS/TBK1 signaling pathway
HPV16 E6 forms a ternary E6-TRIM25-USP15 complex that
reduces TRIM25 protein-stability, leading to reduced
ubiquitination of RIG-I and suppression of its ability to
interact with MAVS.
HEK 293T and the cervical carcinoma-derived cell line C33a
ectopically expressing FLAG-tagged E6 of HPV16. Chiang, C. et al., 2018 [100]
HPV16/18 E7 induces the transcription of SUV39H1, which
promotes epigenetic silencing of RIG-I.
HeLa, CaSki, NIKSmcHPV18 and HEK 293 cells expressing either
HPV16/18 E6 or E7. Albertini, S. et al., 2018 [95]; Lo Cigno, I. et al., 2020 [96]
TLR signaling pathway
HPV16 E6/E7 induce downregulation of TLR9 expression at
both mRNA and protein levels.
Human primary keratinocytes stably transduced with
HPV16E6/E7 expressing retroviruses, HeLa, SiHa and CaSki. Hasan, U.A. et al., 2007 [101]
HPV16 suppresses TLR expression in the cervical mucosa,
contributing to viral persistence. Cervical cytobrush samples.
Daud, I.I. et al., 2011 [102]; Scott, M.E. et al., 2015 [103];
Halec, G. et al., 2018 [104]
PRR-Related Transcription Factors
HPV16 E6 binds IRF3 and impairs its transcriptional activity. In vitro synthesized protein, and HPV16 E6-transfected cells,including primary human keratinocytes. Ronco, L.V. et al., 1998 [93]
HPV16 E7 binds IRF1 and impairs its DNA binding and
transcriptional activity. In vitro synthesized HPV16 E7 and HPV16E7-transfected cells.
Park, J.S. et al., 2000 [90]; Perea, S.E. et al., 2000 [91];
Um, S.J. et al., 2002 [92]
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4.1. cGAS/STING/TBK1
Since the discovery of STING (also known as MPYS, MITA, or ERIS) as a powerful inducer
of IFNs, several putative DNA sensors have been reported to survey the presence of cytosolic
DNA and activate type I IFN production through STING signaling. However, it is now widely
acknowledged that the major pathways mediating the immune response to exogenous DNA rely on
the cGAS–STING axis, as outlined in Figure 1, and for this reason only this pathway will be considered
in this review [40–44,62,105].Pathogens 2020, 9, x FOR PEER REVIEW 6 of 20 
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Upon DNA binding, cGAS converts adenosine 5′-triphosphate (ATP) and guanosine
5′-triphosphate (GTP) into cyclic GMP–AMP (2′3′-cGAMP), which functions as a secondary messenger
that binds and activates STING. Its activation leads to trafficking from the endoplasmic reticulum
(ER) to an ER-Golgi intermediate compartment followed by its migration into the Golgi apparatus
and eventually into the perinuclear regions, where it is degraded. During trafficking, STING recruits
and activates the kinase TBK1, which in turn phosphorylates IRF3, leading to IRF3-mediated IFN
induction [58,60,61].
Even though cGAS–STING signaling is pivotal to withstanding infection by numerous pathogens,
recent studies have unveiled additional functions of this pathway other than antimicrobial immunity.
For instance, the cGAS–STING axis plays a role in activating a sterile cellular stress response, such
as that occurring in cancer cells due to chromosomal abnormality, genomic DNA damage, and
hyperproliferation. As cancer cells often form micronuclei or cytoplasmic DNA that may activate
cGAS–STING signaling, it has become increasingly clear that the inactivation of this pathway is
an efficient strategy for the virus to limit the induction of inflammatory and immune stimulatory
molecules with tumor-killing activity (e.g., cytokines and NK ligands) [59,105–113]. Experimental
results corroborating a model whereby HPV induces transformation and neoplastic progression also
through the inhibition of the cGAS–STING immunomodulatory pathway are outlined below.
The first study showing the direct inhibition of cGAS by HPV oncoproteins was published in 2015
by Lau et al. This group transduced primary embryo fibroblasts (MEFs) with retroviruses expressing
either HPV18 E6 or E7 and found that those transduced with E7, but not E6, lost their ability to secrete
type I IFN in response to exogenous DNA stimulation. By contrast, the authors failed to observe any
inhibition when RIG-I agonists were used to stimulate these cells. Of note, they could not demonstrate
any direct interaction between E7 and cGAS, while they were able to co-immunoprecipitate STING
and E7 by overexpressing a Flag-STING construct in HeLa cells, a cervical carcinoma-derived cell
line harboring integrated HPV18 DNA. Consistent with an immune suppressing activity of HPV18,
disruption of the E7 gene in HeLa cells through a lenti-CRISPR-Cas9 approach restored responsiveness
to exogenous DNA in terms of IFN production [94].
These findings were later confirmed and further strengthened by a study from our group showing
that keratinocytes stably harboring multiple copies of hrHPV18 genome (i.e., NIKSmcHPV18), as well
as HeLa cells, displayed a marked transcriptional downregulation of the PRRs cGAS, its downstream
adaptor STING, and, to a lower extent, RIG-I. Likewise, we observed reduced expression levels of the
transcription factors IRF1 and 7. It is important to point out that, in our experiments, we exclusively
used NIKSmcHPV18 cells grown between passages 20 and 30, when E6 and E7 transcripts are higher
than that of E2, an expression pattern typical of persistent HPV infection. Overall, our findings
indicate that the HPV-induced repression of PRR signaling is probably the reason why keratinocytes
can maintain a high copy number of episomal viral DNA without triggering an antiviral response.
Fittingly, we demonstrated that HPV18 persistence in keratinocytes inhibits both type I and III IFN
production in response to DNA ligands, and that this effect is mainly due to suppression of the
cGAS–STING pathway, which seems to be irreversible even after treatment with exogenous DNA.
The downregulation of cGAS–STING signaling occurred through transcriptional repression of each
single component via a novel epigenetic silencing mechanism, as attested by the accumulation of
repressive heterochromatin markers, mainly H3K9me2, at the promoter region of RIG-I, cGAS, and
STING genes [95]. We also showed that the accumulation of this repressive marker was due to
the E7-dependent transcriptional induction of the H3K9-specific methyltransferase SUV39H1, the
human homolog of the Drosophila Su(var)3-9 histone methyltransferase, which triggers histone
H3Lys9 trimethylation (H3K9me3), inducing a chromatin conformational transition from an open
to a closed state. In good agreement, the drug-induced inactivation or gene silencing of SUV39H1
disrupted H3K9me2/me3 binding to the promoter regions of RIG-I, cGAS, and STING, promoting
the transcriptional activation of RIG-I and cGAS alongside an augmented secretion of type I and III
IFNs. Importantly, SUV39H1-mediated chromatin remodeling in HPV18-harboring HeLa cells was
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similar to that observed in HPV16-harboring CaSki cells [114], implying that both hr genotypes have
developed evolutionarily conserved strategies to epigenetically overturn the mechanisms of immune
surveillance [96].
Another significant breakthrough to the field was later made by Luo et al. who provided the
first evidence that the HPV-mediated inhibition of the STING signaling pathway may also play a
significant role in the biology of head and neck squamous cell carcinoma (HNSCC). Through tissue
microarray analysis of 297 HNSCCs (32% HPV+ and 60% HPV−), Luo and co-workers were able
to demonstrate that high STING scores in the parenchyma and tumor microenvironment (TME) of
these tumors correlated with improved patient survival. When the variables age, stage, site, HPV,
and smoking habits were taken into account by multivariate Cox regression, they found that STING
scores in the tumor parenchyma but not TME were still indicative of better survival rates, underscoring
the prognostic value of STING expression in HNSCC patients. The same authors went on showing
that STING expression levels, as well as those of TBK1 phosphorylation, were strongly reduced upon
the exogenous expression of HPV16 E7 in a panel of HNSCC-derived cell lines. Consistently, these
events were accompanied by reduced type I IFN induction upon poly(dA:dT) transfection, while
E7 depletion in HPV16+ HNSCC cells restored IFN production following exogenous stimulation.
Importantly, they found that HPV16 E7 but not HPV18 E7 hijacks NLRX1 to induce STING degradation
via an autophagy-dependent mechanism, thereby providing a mechanism of STING downregulation
in HNSCC cells where HPV16E7 does not bind STING [97].
Although first implicated in immune regulation, NLRX1 was later shown to regulate the
mitochondrial pathway of apoptosis and IFN production via MAVS-RLR signaling. Specifically,
NLRX1 attenuated type I IFN production while promoting autophagy during viral infection. NLRX1
is a component of a regulatory mitochondrial protein complex that also comprises the mitochondrial
Tu translation elongation factor (TUFM), which, following viral infection, mediates the induction
of IFN-I and autophagy through RIG-I and the autophagy-related proteins Atg5-Atg12 conjugate
and Atg16L1 [115–117]. In this regard, Luo et al. found that NLRX1/E7 interaction contributed to
enhanced STING turnover in HNSCC cells. Thanks to a newly characterized HPV16 E6/E7-expressing
HNSCC mouse model (MOC2-E6/E7), syngeneic to C57BL/6, they also demonstrated that the
CRISPR/Cas9-mediated depletion of NLRX1 in tumor cells could significantly increase STING activation
upon poly(dA:dT) stimulation, as determined by the enhanced expression levels of TNF-α, IL-6 and
IFNβ1, key markers of STING-mediated downstream effector activation. They also found that the
depletion of NLRX1 in tumor cells significantly reduced the number of tumor-infiltrating lymphocytes in
an IFN-dependent fashion accompanied by a more efficient cytotoxic T lymphocytes (CTLs) expansion
in the draining lymph nodes [97].
Consistent with the epigenetic downregulation of STING gene expression in cancer cells hampering
IFN and cytokine production upon cytosolic DNA stimulation, Qin Yan and collaborators demonstrated
that STING mRNA expression is epigenetically downregulated by the histone H3K4 lysine demethylases
KDM5B and KDM5C, whereas it is activated by H3K4 methyltransferases. In breast cancer cells,
following KDM5 inhibition, STING expression was upregulated, thereby permitting interferon
production in response to cytosolic DNA. Of note, a negative correlation between KDM5B and STING
expression was similarly observed in HPV+ head and neck and cervical cancers. The expression
of KDM5B was also negatively associated with CXCL10 expression—i.e., the interferon-inducible
chemokine promoting infiltration of immune cells into the tumor microenvironment—and CD8+ T-cell
infiltration [98].
In addition, the dampening of the cGAS–STING signaling pathways has also been reported in
a panel of HNSCC-derived cell lines with the documented expression of HPV16 E7. Accordingly,
in these cell lines, IFNβ induction upon stimulation with salmon sperm or 2′3′-cGAMP, two potent
agonists of this pathway, was significantly impaired when compared to HPV− HNSCC-derived cell
lines. Conversely, no significant difference in terms of IFN induction upon 5′ppp-dsRNA stimulation
was observed between HPV+ and HPV− cell lines, indicating that the RIG-I signaling pathway is not
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impaired by HPV16 E7 expression, at least in the cell lines tested. One limitation of this study is that
IFN induction was only measured at the mRNA level [99].
Collectively, the aforementioned seminal studies uncover a novel strategy of HPV16 immune
evasion aimed at reducing the availability of the key innate immune sentinel STING. Since NLRX1 has
also been reported to regulate the MAVS/RLR signaling pathway, one may envisage that impairment of
RIG-I functions may also be a common feature of HPV16-associated cancers, a hypothesis that awaits
further confirmation.
4.2. RIG-I/MAVS/TBK1
While various sensors play a role in recognizing non-self DNA when aberrantly expressed or
localized within a cell, RLRs appear to be the sole receptors involved in the cytosolic recognition
of viral RNA, with RIG-I being the founding member of the family. Although RIG-I was originally
identified as a crucial cytoplasmic sensor surveying the presence of RNA viruses, mounting evidence
indicates that it also plays a role in detecting several DNA viruses as well as RNA species generated
by RNA polymerase III [118,119]. In addition, physical and functional interconnections between
RIG-I and STING have been reported during infection with both RNA and DNA viruses, which are
often associated with enhanced antiviral response. The role of STING in mediating RIG-I signaling is
so crucial that many RNA viruses have learned how to block this signaling cascade to escape from
immunosurveillance [41,120–125]. Whether this interconnection also exists in the case of HPV remains
to be clarified.
RLRs, such as RIG-I and MDA5, harbor a central DEAD box helicase/ATPase domain and
a C-terminal regulatory domain (CTD), required for RNA binding and, at least for RIG-I, the
self-repression of RLR activity. As depicted in Figure 2, upon binding of 5′-ppp-RNA to the CTD/helicase
region, RIG-I is regulated by a series of post-translational modifications (e.g., dephosphorylation and
ubiquitination) and ATP-dependent conformational changes that promote its oligomerization and
binding to the adaptor MAVS. Once activated, RIG-I/MAVS signaling bifurcates into two distinct
molecular cascades: one pathway involves the TBK1 and IκB kinase ε (IKKε), which directly
phosphorylate IRF3/7 to transcriptionally activate type I and type III IFNs; the other pathway
engages the IKKα/β/γ complex, which promotes NF-κB-dependent upregulation of proinflammatory
genes (Figure 2) [53,54,100,121,122,126].
Although to date there is no evidence of the involvement of RIG-I in HPV sensing, the inactivation
of this signaling pathway through distinct mechanisms has been reported. In particular, Chiang
et al. demonstrated that HPV16 E6 forms a complex with TRIM25 and its upstream regulator, the
ubiquitin-specific protease 15 (USP15). As TRIM25 protein stability is regulated by the balance between
degradative K48-linked ubiquitination and USP15-mediated deubiquitination, the authors performed
coimmunoprecipitation experiments in HEK 293T and cervical-carcinoma-derived C33a cells ectopically
expressing FLAG-tagged E6 of HPV16, showing that E6 binds exogenous TRIM25 and USP15, giving
rise to a ternary E6-TRIM25-USP15 complex. Enhanced E6-driven TRIM25 polyubiquitination led to
reduced TRIM25 protein-stability. It is worth noting that the ability of E6 to form a ternary complex
was also observed in other hr and low-risk HPVs from the alpha genus. In contrast, E7 from the
same genotypes failed to bind TRIM25, indicating specificity of this inhibitory cascade. Consistently,
enhanced TRIM25 destabilization in HPV16E6 expressing cells hindered the interaction of RIG-I
with its downstream adaptor mitochondrial antiviral signaling protein (MAVS) upon Sendai virus
infection. As expected, the ectopic expression of HPV16 E6 but not E7 in these cells strongly inhibited
the RIG-I-mediated induction of ISGs [100,126]. Although the authors provide compelling evidence
that the ectopic expression of E6 can suppress TRIM25-dependent K63-linked ubiquitination of RIG-I
and its caspase activation and recruitment domain (CARD) dependent interaction with MAVS, RIG-I
ubiquitination status and activity in HPV-transformed cells, such as HeLa or CaSki, was not assessed.
The latter would have allowed the authors to corroborate their findings in a cell environment where
both E6 and E7 are expressed as it occurs in HPV-driven cancer. Considering that our group has
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recently reported the SUV39H1-dependent epigenetic silencing of RIG-I in HPV-transformed cells (i.e.,
HPV16, HPV18, and HPV31), it will be crucial to determine whether the E6-mediated post-translational
modification of TRIM25 and E7-induced transcriptional repression of RIG-I are two coexisting and
convergent pathways of HPV immune escape [95,96].
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4.3. TLRs
TLRs are expressed on the cell surface and in endosomal compartments to respond to extracellular
and endosomal PAMPs or danger associated molecular patterns (DAMPs), produced by cells in distress,
such as that caused by viral infections. Cell surface TLRs mainly recognize microbial membrane
components. In particular, TLR4 binds bacterial lipopolysaccharide (LPS), whereas TLR1, TLR2, and
TLR6 recognize a large number of PAMPs, such as peptidoglycans, lipoproteins, and lipoteichoic
acids. In addition, TLR5 specifically senses bacterial flagellin. In contrast, TLRs 3, 7, 8, and 9 generally
localize to endosomal membranes, where they sense a wide range of nucleic acids derived from
viruses as well as endogenous nucleic acids that exit the nuclei under stress conditions. As outlined
in Figure 3, upon dsRNA binding, TLR3 regulates the activation of the transcription factor IRF3
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that induces the expression of IFNs. TLR7 and TLR8 recognize ssRNA, whereas TLR9 binds DNA
containing unmethylated cytosine-phosphate-guanosine (CpG) motifs. TLRs 7, 8, and 9 act through the
myeloid differentiation primary response gene 88 (MyD88) pathway, which promotes the recruitment
of downstream signaling molecules such as kinases that phosphorylate the inhibitor of kappa-B (IκB)
to induce nuclear factor kappa-light chain-enhancer of activated B cells (NF-κB) signaling or IRF7 to
induce the expression of type IFNs or proinflammatory cytokine genes, respectively [45,46,127].Pathogens 2020, 9, x FOR PEER REVIEW 11 of 20 
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Immortalized epithelial cells from the lower female reproductive tract, including End1/E6E7 were
reported to express mRNA for all 10 human TLRs, with the exception of TLR4 [128]. Tommasino and
co-workers reported the down regulation of TLR9 expression at both the mRNA and protein levels in
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HPV16 E6/E7-transduced keratinocytes. TLR9 suppression occurred at the transcriptional level as no
TLR9 transcript was found in any of the three HPV16 E6/E7 keratinocyte lines generated independently
using primary cells from different donors. Conversely, in three HPV18 E6/E7-transduced cell lines, the
authors could not detect any significant variation in TLR9 mRNA levels when compared to normal
keratinocytes. A similar trend was found in cervical carcinoma-derived cell lines. Specifically, SiHa
and CaSki cells, containing an integrated HPV16 DNA, displayed respectively weak and undetectable
levels of TLR9 mRNA, whereas HeLa cells, harboring an integrated HPV18, showed much higher
TLR9 mRNA expression levels than those seen in SiHa, confirming the lower efficiency of HPV18 in
inhibiting TLR9 transcription. Accordingly, TLR9 downregulation was also observed in cervical cancer
biopsies by immunohistochemistry [101].
The inhibition of TLR expression was also observed in other studies assessing mRNA expression
levels of TLR2, TLR3, TLR7, TLR8, and TLR9 genes in cervical cytobrush samples. In particular, it was
found a significant association between enhanced TLR3 or TLR7 expression at an HPV16-positive
visit and clearance by the following visit. These higher TLR expression levels were associated with
increased levels of IFNα2, as judged by immunoassay in cervical lavage specimens. Accordingly,
women with CIN2 regression had significantly higher baseline levels of TLR2, TLR7, and TLR8 when
compared to women with CIN2 persistence/progression [102–104].
Collectively, these clinical data point to a critical role of TLRs in controlling HPV16 infection and
suggest that the dampening of TLR expression in the cervical mucosa is a mechanism whereby HPV16
interferes with innate immune responses, contributing to viral persistence. However, despite the
aforementioned clinical evidence, the underlying mechanisms of the HPV16-mediated downregulation
of TLRs have yet to be fully characterized.
4.4. PRR-Related Transcription Factors
Lastly, it is worth considering two earlier studies showing for the first time the E6/E7-mediated
inhibition of IRF1/3 transcriptional activity. Although this inhibition was initially thought to impair
IFN activity, we now know that the same players are also involved in PRR signaling, indicating that
HPV viral oncoproteins can tamper with downstream effectors of PRRs as well. In particular, HPV16
E6, but not HPV18 E6, was shown to bind and suppress the transcriptional activity of IRF3. More
recently, Sangdun Choi and collaborators performed a series of in silico examinations, indicating
that the LxxLL motifs of IRF3 binds within the hydrophobic pocket of E6, thus precluding Ser-patch
phosphorylation, necessary for IRF3 activation and IFN induction. However, these data have yet
to be confirmed experimentally. IRF1 is also a target of HPV16 E7 as its expression was reported to
abrogate IRF1 DNA binding activity. A physical interaction between IRF1 and E7 that requires the
carboxyl-terminal transactivation domain of IRF1 and the pRb-binding portion of E7 has also been
reported [90–93,129].
5. Concluding Remarks and Future Perspectives
In conclusion, we have reviewed past and current literature addressing common strategies evolved
by hrHPV genotypes to subvert the innate immune response in keratinocytes and create an unreactive
cellular milieu conducive to cell transformation. The hallmark of HPV persistence—the conditio
sine qua non of cancer development—is undoubtedly the deregulated expression of the two viral
oncoproteins E6 and E7, whose most regarded function is that of interfering with the tumor suppressors
p53 and pRb. By targeting cell cycle checkpoints and apoptosis pathways, E6 and E7 put host cells
at increased risk for cellular genomic instability and chromosome abnormality, major driving forces
of carcinogenesis. On the other hand, host cells are equipped with several stringent and intertwined
signaling pathways that enable them to maintain genome integrity through the immune clearance of
damaged cells, thereby preventing malignant transformation.
Even though DNA damage response has been largely implicated in the regulation of genome
integrity and cell death, recent findings have established a relationship between genomic instability
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and inflammation. In particular, recent studies have provided mechanistic insights into how DNA
damage elicits the production of type I IFNs and other immunoregulatory cytokines. These events are
mainly triggered by the localization of DNA to the cytoplasm, mostly in the form of micronuclei, which,
after being sensed by cytoplasmic PRRs, trigger downstream signaling cascades [59,108,130,131].
Consistent with cGAS–STING signaling playing a major role in the activation of IFNs and
cytokines responsible for the clearance of potentially carcinogenic damaged/stressed cells, the frequent
suppression of cGAS and STING expression or function has been reported in many types of human
malignancies [105–108,131,132]. Accordingly, the impact of E6/E7 on innate immunity rather than
cell proliferation has gained increasing attention as one of the major determinants of HPV-induced
carcinogenesis. Notably, the observed inhibition of cGAS–STING signaling in HPV-transformed
cells may also provide an explanation as to why cells harboring hrHPV infection are still capable of
replicating despite the activation of the DNA damage response, which would otherwise arrest cellular
replication by triggering the innate immune response [108,131,133,134].
While the immune evasion strategies evolved by HPV to establish viral latency have already been
extensively addressed, we have summarized a growing body of literature echoing that the dampening
of the innate immune response by E6/E7 plays an equally important role in tumor development.
Another important take-home message is that HPV, thanks to the concerted actions of E6 and E7, has
evolved multi-faceted mechanisms aimed to curb multiple rather than single downstream effectors
of the immunosurveillance network. In particular, E7 appears to be mostly responsible for PRR
suppression. The nature of this inhibition, including the reversibility of the modifications determined
by E7 expression, seems to be quite different, especially when we consider the cGAS–STING and RIG-I
signaling pathways [94–100]. Indeed, while the former is heavily impaired in HPV-transformed cells,
and thus hardly reactivatable, RIG-I signaling is still partially functional, and when stimulated by
powerful agonist, e.g., M8, it can boost a relatively large amount of IFNs, especially type III IFN [95,96].
Therefore, the specific targeting of immune pathways such as RIG-I appears to be an attractive and
feasible option to trigger the innate immune response in HPV-transformed cells. Considering the
emerging role of M8 as inducer of immunogenic cell death in cancer cells through the production
of type I IFNs and lymphocyte-recruiting chemokines, this compound may be a suitable candidate
to enhance cell death in HPV-transformed cells and improve the effectiveness of existing anticancer
therapies in HPV-associated tumors in vivo [135–139].
It is our hope that the findings and ideas discussed herein will spur cross-disciplinary investigations
aimed at clarifying the functional role of viral oncoproteins at the intersection of immune evasion and
aberrant proliferation in HPV-associated cancers, with the long-range goal to discover novel targets for
therapeutic development.
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